Larisa H Cavallari, Pharm.D., BCPS, FCCP
Professor And Debbie DeSantis Term Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 273-8245
Business Email:
lcavallari@ufl.edu
About Larisa H Cavallari
Dr. Cavallari received her B.S. Pharmacy and Pharm.D. degrees from the University of Georgia. She then completed a Pharmacy Practice Residency at the Veterans Affairs Medical Center in Memphis, Tennessee and a fellowship in Cardiovascular Pharmacogenomics at the University of Florida. Dr. Cavallari accepted a position as an Assistant Professor of Pharmacy Practice at the University of Illinois at Chicago after completing her training and was promoted to Associate Professor in 2009. While at UIC, she directed efforts to implement genotype-guided warfarin dosing for all patients newly starting warfarin during hospitalization. Dr. Cavallari joined the University of Florida Department of Pharmacotherapy and Translational Research as an Associate Professor in April, 2014, where she serves as co-director of the Center for Pharmacogenomics and Precision Medicine. She also serves as Director of the UF Health Precision Medicine Program. In 2021, she was promoted to professor. Her research involves discovery and clinical translation of genetic variants related to drug response and has been funded by the NIH, FDA, American Heart Association, and other awards.
Dr. Cavallari has served on both NIH and American Heart Association grant review committees and is a Board Certified Pharmacotherapy Specialist, Fellow of the American College of Clinical Pharmacy, former Chair of the American College of Clinical Pharmacy Research Institute, and Editorial Board Member for the Lexi-Comp pharmacogenetics series.
Accomplishments
Elected Regent
2019
·
American College of Clinical Pharmacy
Elected Trustee
2013-2016
·
Research Institute, American College of Clinical Pharmacy
Best Paper
2009
·
International Congress on Clinical Pharmacy
Kenneth F. Finger Fellow Alumni Lecturer Award
2009
·
University of Florida
Fellow
2008
·
American College of Clinical Pharmacy
Hans Vahlteich Research Award
2007
·
University of Illinois at Chicago
Faculty New Investigator
2004
·
American Association of Colleges of Pharmacy-American Foundation for Pharmaceutical Education Pharmacy
Annual Meeting Best Student, Resident, Fellow Paper Award
2000
·
American College of Clinical Pharmacy
Kenneth F. Finger Memorial Award for Excellence in Clinical Pharmacy Research
2000
·
University of Florida
American Foundation for Pharmaceutical Education for the Biomedical Research Sciences Fellow
1999-2000
·
University of Florida
Teaching Profile
Courses Taught
2019-2020,2023-2024
PHA5930 Sem Pharm Research
2016-2018,2020-2023,2022-2023
PHA5878C Pt Care 3: Cv and Pulm
2015-2016,2018-2024,2023-2024
PHA7980 Research for Doctoral Dissertation
2015-2024
PHA7979 Advanced Research
2020-2024
PHA6910 Supervised Research
2020-2024
PHA6935 Selected Topics in Pharmacy
2017-2019,2022-2024
PHA5012 App Personalized Med
2017-2018
PHA5788C Patient Care 6
2018
ANG7980 Research for Doctoral Dissertation
2018
PHA5907 Research in Phar Prac
2018
PHA5876C Pt Care 8 Complex Pts
2016,2018-2021,2021-2022
PHA6938 Research Seminar
2016,2021
PHA6971 Research for Master’s Thesis
2014-2015
PHA5782 Pharmacotherapy 2
2014-2015
PHA5113 Personalized Medicine
2015
PHA6633 Medication Therapy Management: A Cardiovascular Focus
2021
PHA6894 Introduction to Graduate Studies
2023-2024
PHA6185 Life Cycle of a Drug
Clinical Profile
Specialties
- Pharmacy
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-7184-5292
Publications
2024
Assessing the Performance of In silico Tools and Molecular Dynamics Simulations for Predicting Pharmacogenetic Variant Impact
Clinical Pharmacology & Therapeutics.
[DOI] 10.1002/cpt.3348.
2024
Assessing user perspectives on clinical pharmacogenomics consultation documentation: a user-centered evaluation.
Frontiers in pharmacology.
15
[DOI] 10.3389/fphar.2024.1377132.
[PMID] 38783934.
2024
Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.
JACC. Basic to translational science.
9(7):865-876
[DOI] 10.1016/j.jacbts.2024.03.003.
[PMID] 39170956.
2024
CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association.
Circulation.
150(6):e129-e150
[DOI] 10.1161/CIR.0000000000001257.
[PMID] 38899464.
2024
CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention
Journal of the American Heart Association.
13(12)
[DOI] 10.1161/jaha.123.033791.
2024
Decoding pharmacogenomic test interpretation and application to patient care
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.
7(6):581-588
[DOI] 10.1002/jac5.1958.
2024
DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium.
The Journal of molecular diagnostics : JMD.
[DOI] 10.1016/j.jmoldx.2024.05.015.
[PMID] 39032821.
2024
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score.
Journal of the American College of Cardiology.
83(15):1370-1381
[DOI] 10.1016/j.jacc.2024.02.015.
[PMID] 38599713.
2024
Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction
Clinical Pharmacology & Therapeutics.
[DOI] 10.1002/cpt.3385.
2024
Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients
Clinical and Translational Science.
17(1)
[DOI] 10.1111/cts.13692.
[PMID] 38013396.
2024
Genotype-Guided De-Escalation of DAPT: Switching to Real-World Practice.
JACC. Cardiovascular interventions.
[DOI] 10.1016/j.jcin.2024.07.014.
[PMID] 39217532.
2024
Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators
Clinical and Translational Science.
17(8)
[DOI] 10.1111/cts.70005.
[PMID] 39177194.
2024
Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR
Clinical Pharmacology & Therapeutics.
116(3):795-806
[DOI] 10.1002/cpt.3274.
2024
Meta-analysis of genome-wide association studies of stable warfarin dose in patients of African ancestry.
Blood advances.
[DOI] 10.1182/bloodadvances.2024014227.
[PMID] 39163621.
2024
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies
Clinical and Translational Science.
17(8)
[DOI] 10.1111/cts.70004.
[PMID] 39150361.
2024
Rationale and design for a pragmatic randomized trial to assess gene‐based prescribing for SSRIs in the treatment of depression
Clinical and Translational Science.
17(6)
[DOI] 10.1111/cts.13822.
[PMID] 38860639.
2023
A pilot study to identify pharmacogenomic and clinical risk factors associated with opioid related falls and adverse effects in older adults
Clinical and Translational Science.
16(11):2331-2344
[DOI] 10.1111/cts.13634.
[PMID] 37705211.
2023
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
Clinical Pharmacology & Therapeutics.
114(2):275-287
[DOI] 10.1002/cpt.2957.
[PMID] 37303270.
2023
Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
JAMA network open.
6(4)
[DOI] 10.1001/jamanetworkopen.2023.8585.
[PMID] 37067798.
2023
Clinician Response to Pharmacogenetic Clinical Decision Support Alerts
Clinical Pharmacology & Therapeutics.
114(6):1350-1357
[DOI] 10.1002/cpt.3051.
[PMID] 37716912.
2023
CYP2D6‐guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
43(12):1286-1296
[DOI] 10.1002/phar.2875.
[PMID] 37698371.
2023
CYP3A4 and CYP3A5 Genotyping Recommendations
The Journal of Molecular Diagnostics.
25(9):619-629
[DOI] 10.1016/j.jmoldx.2023.06.008.
[PMID] 37419245.
2023
Evaluation of Potential Racial Disparities in CYP2C19‐Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention
Clinical Pharmacology & Therapeutics.
113(3):615-623
[DOI] 10.1002/cpt.2776.
[PMID] 36306392.
2023
Genomewide Association Study Identifies Copy Number Variants Associated With Warfarin Dose Response and Risk of Venous Thromboembolism in African Americans
Clinical Pharmacology & Therapeutics.
113(3):624-633
[DOI] 10.1002/cpt.2820.
[PMID] 36507737.
2023
Genotype-Guided Selection of Antiplatelet Therapy: The Evidence Moves East.
JACC. Cardiovascular interventions.
16(7):844-846
[DOI] 10.1016/j.jcin.2023.02.021.
[PMID] 36898938.
2023
Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
80(15):994-1003
[DOI] 10.1093/ajhp/zxad099.
[PMID] 37166240.
2023
Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan.
Frontiers in genetics.
14
[DOI] 10.3389/fgene.2023.1249003.
[PMID] 37680199.
2023
Local Ancestry‐Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations
Clinical Pharmacology & Therapeutics.
113(3):680-691
[DOI] 10.1002/cpt.2787.
[PMID] 36321873.
2023
Pharmacist-Guided Pharmacogenetic Service Lowered Warfarin-Related Hospitalizations
Pharmacogenomics.
24(6):303-314
[DOI] 10.2217/pgs-2023-0014.
2023
Pharmacogenetics of P2Y12 receptor inhibitors
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
43(2):158-175
[DOI] 10.1002/phar.2758.
[PMID] 36588476.
2023
Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States.
Frontiers in pharmacology.
14
[DOI] 10.3389/fphar.2023.1179364.
[PMID] 37645439.
2023
Use of a multi-gene pharmacogenetic panel reduces adverse drug effects.
Cell reports. Medicine.
4(5)
[DOI] 10.1016/j.xcrm.2023.101021.
[PMID] 37084734.
2022
A randomized, cross‐over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence
Clinical and Translational Science.
15(7):1764-1775
[DOI] 10.1111/cts.13294.
[PMID] 35488487.
2022
Best-worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy.
Implementation science communications.
3(1)
[DOI] 10.1186/s43058-022-00300-7.
[PMID] 35568931.
2022
Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing.
Clinics in laboratory medicine.
42(4):533-546
[DOI] 10.1016/j.cll.2022.09.009.
[PMID] 36368780.
2022
Changing from Mandatory to Optional Genotyping Results in Higher Acceptance of Pharmacist-Guided Warfarin Dosing
Pharmacogenomics.
23(2):85-95
[DOI] 10.2217/pgs-2021-0109.
2022
Characterizing OPRM1 DNA methylation in prescription opioid users with chronic musculoskeletal pain.
Pain reports.
7(6)
[DOI] 10.1097/PR9.0000000000001046.
[PMID] 36447952.
2022
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
European heart journal.
43(10):959-967
[DOI] 10.1093/eurheartj/ehab836.
[PMID] 34918066.
2022
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Journal of the American Heart Association.
11(4)
[DOI] 10.1161/JAHA.121.024159.
[PMID] 35156424.
2022
Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation.
Pharmacogenetics and genomics.
32(5):183-191
[DOI] 10.1097/FPC.0000000000000469.
[PMID] 35389962.
2022
Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy.
Frontiers in cardiovascular medicine.
9
[DOI] 10.3389/fcvm.2022.991646.
[PMID] 36082121.
2022
Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers
The Pharmacogenomics Journal.
22(1):62-68
[DOI] 10.1038/s41397-021-00257-1.
[PMID] 34642472.
2022
How to implement a pharmacogenetics service at your institution
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.
5(11):1161-1175
[DOI] 10.1002/jac5.1699.
[PMID] 36589694.
2022
Identification of a SGCD × Discrimination Interaction Effect on Systolic Blood Pressure in African American Adults in the Jackson Heart Study
American Journal of Hypertension.
35(11):938-947
[DOI] 10.1093/ajh/hpac098.
[PMID] 35999027.
2022
Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Clinical pharmacology and therapeutics.
112(1):146-155
[DOI] 10.1002/cpt.2612.
[PMID] 35429163.
2022
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators
Clinical and Translational Science.
15(10):2479-2492
[DOI] 10.1111/cts.13376.
[PMID] 35899435.
2022
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy
Clinical and Translational Science.
15(2):371-383
[DOI] 10.1111/cts.13154.
[PMID] 34562070.
2022
Pharmacogenetics: A precision medicine approach to combatting the opioid epidemic
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.
5(2):239-250
[DOI] 10.1002/jac5.1582.
[PMID] 35784584.
2022
TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase
The Journal of Molecular Diagnostics.
24(10):1051-1063
[DOI] 10.1016/j.jmoldx.2022.06.007.
[PMID] 35931343.
2022
Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.
Clinical pharmacology and therapeutics.
111(4):950-955
[DOI] 10.1002/cpt.2549.
[PMID] 35108398.
2022
β1-receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery.
Clinical and translational science.
15(3):619-625
[DOI] 10.1111/cts.13178.
[PMID] 34713976.
2021
A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management
Genetics in Medicine.
23(4):621-628
[DOI] 10.1038/s41436-020-01050-4.
[PMID] 33420349.
2021
Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic.
Clinical and translational science.
14(2):589-598
[DOI] 10.1111/cts.12914.
[PMID] 33166056.
2021
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Clinical pharmacology and therapeutics.
109(6):1417-1423
[DOI] 10.1002/cpt.2015.
[PMID] 32770672.
2021
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
Clinical pharmacology and therapeutics.
110(4):888-896
[DOI] 10.1002/cpt.2149.
[PMID] 33387367.
2021
Corrigendum to “Periprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study”. [Current Problems in Cardiology Volume 46, Issue 6, June 2021, 100816].
Current problems in cardiology.
46(12)
[DOI] 10.1016/j.cpcardiol.2021.100899.
[PMID] 34154818.
2021
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model
The Pharmacogenomics Journal.
21(4):476-483
[DOI] 10.1038/s41397-021-00225-9.
[PMID] 33824430.
2021
Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating Cis-Regulatory Quantitative Effects.
Frontiers in genetics.
12
[DOI] 10.3389/fgene.2021.701405.
[PMID] 34408773.
2021
Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease
The Pharmacogenomics Journal.
21(6):657-663
[DOI] 10.1038/s41397-021-00244-6.
[PMID] 34075203.
2021
Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(7):1185-1191
[DOI] 10.1038/s41436-021-01118-9.
[PMID] 33782552.
2021
Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics
Journal of the American College of Clinical Pharmacy.
4:343-351
[DOI] 10.1002/jac5.1335.
2021
Genetic and Non-Genetic Factors Impact on INR Normalization in Preprocedural Warfarin Management.
Pharmacogenomics and personalized medicine.
14:1069-1080
[DOI] 10.2147/PGPM.S322743.
[PMID] 34483679.
2021
Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations.
Expert review of clinical pharmacology.
14(8):963-978
[DOI] 10.1080/17512433.2021.1927709.
[PMID] 33993817.
2021
How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.
Clinical pharmacology and therapeutics.
110(3):677-687
[DOI] 10.1002/cpt.2354.
[PMID] 34231197.
2021
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Clinical pharmacology and therapeutics.
109(3):705-715
[DOI] 10.1002/cpt.2039.
[PMID] 32897581.
2021
Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
Clinical and translational science.
14(2):492-496
[DOI] 10.1111/cts.12939.
[PMID] 33278335.
2021
Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans.
Frontiers in pharmacology.
12
[DOI] 10.3389/fphar.2021.749786.
[PMID] 34776967.
2021
Moving Pharmacogenetics Into Practice: It’s All About the Evidence!
Clinical pharmacology and therapeutics.
110(3):649-661
[DOI] 10.1002/cpt.2327.
[PMID] 34101169.
2021
Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos.
Clinical and translational science.
14(1):268-276
[DOI] 10.1111/cts.12854.
[PMID] 32860733.
2021
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(12):2335-2341
[DOI] 10.1038/s41436-021-01269-9.
[PMID] 34282303.
2021
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo‐DHF trial
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.
41(12):978-987
[DOI] 10.1002/phar.2626.
[PMID] 34569641.
2021
Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.
Clinical pharmacology and therapeutics.
110(1):179-188
[DOI] 10.1002/cpt.2161.
[PMID] 33428770.
2021
Periprocedural Anticoagulation Management of Patients receiving Warfarin in Qatar: A Prospective Cohort Study.
Current problems in cardiology.
46(6)
[DOI] 10.1016/j.cpcardiol.2021.100816.
[PMID] 33721568.
2021
Pharmacogenetics to guide cardiovascular drug therapy
Nature Reviews Cardiology.
18(9):649-665
[DOI] 10.1038/s41569-021-00549-w.
[PMID] 33953382.
2021
PharmVar GeneFocus: CYP2C19.
Clinical pharmacology and therapeutics.
109(2):352-366
[DOI] 10.1002/cpt.1973.
[PMID] 32602114.
2021
PharmVar GeneFocus: CYP2C9.
Clinical pharmacology and therapeutics.
110(3):662-676
[DOI] 10.1002/cpt.2333.
[PMID] 34109627.
2021
Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.
The Journal of molecular diagnostics : JMD.
23(9):1047-1064
[DOI] 10.1016/j.jmoldx.2021.05.013.
[PMID] 34118403.
2021
Utilizing a Human-Computer Interaction Approach to Evaluate the Design of Current Pharmacogenomics Clinical Decision Support.
Journal of personalized medicine.
11(11)
[DOI] 10.3390/jpm11111227.
[PMID] 34834578.
2020
A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications.
Clinical pharmacology and therapeutics.
108(1):116-125
[DOI] 10.1002/cpt.1768.
[PMID] 31910286.
2020
Beta-Blocker Dose Stratifies Mortality Risk in a Racially Diverse Heart Failure Population.
Journal of cardiovascular pharmacology.
75(3):250-258
[DOI] 10.1097/FJC.0000000000000779.
[PMID] 31895871.
2020
Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention.
Clinical and translational science.
13(3):473-481
[DOI] 10.1111/cts.12729.
[PMID] 31758664.
2020
Correction: Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics.
22(11)
[DOI] 10.1038/s41436-020-0931-1.
[PMID] 32747766.
2020
Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data.
The pharmacogenomics journal.
20(5):724-735
[DOI] 10.1038/s41397-020-0162-5.
[PMID] 32042096.
2020
Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic.
Journal of clinical medicine.
9(7)
[DOI] 10.3390/jcm9072274.
[PMID] 32708920.
2020
Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network.
Pharmacogenomics and personalized medicine.
13:217-226
[DOI] 10.2147/PGPM.S241599.
[PMID] 32765043.
2020
Effect of Genetic and Nongenetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure.
Clinical and translational science.
13(1):195-203
[DOI] 10.1111/cts.12702.
[PMID] 31560448.
2020
Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.
Genetics in medicine : official journal of the American College of Medical Genetics.
22(11):1898-1902
[DOI] 10.1038/s41436-020-0894-2.
[PMID] 32678355.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology.
9(12):678-685
[DOI] 10.1002/psp4.12563.
[PMID] 33067866.
2020
Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
Genetics in medicine : official journal of the American College of Medical Genetics.
22(1):160-169
[DOI] 10.1038/s41436-019-0611-1.
[PMID] 31316169.
2020
Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
Clinical pharmacology and therapeutics.
107(6):1420-1433
[DOI] 10.1002/cpt.1755.
[PMID] 31869433.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics.
108(3):557-565
[DOI] 10.1002/cpt.1912.
[PMID] 32460360.
2020
Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
JAMA network open.
3(12)
[DOI] 10.1001/jamanetworkopen.2020.29411.
[PMID] 33315113.
2020
Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.
The Journal of molecular diagnostics : JMD.
22(7):847-859
[DOI] 10.1016/j.jmoldx.2020.04.204.
[PMID] 32380173.
2020
The effect of genetic and nongenetic factors on warfarin dose variability in Qatari population.
The pharmacogenomics journal.
20(2):277-284
[DOI] 10.1038/s41397-019-0116-y.
[PMID] 31653973.
2019
A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary angioplasty.
Future cardiology.
15(4):251-254
[DOI] 10.2217/fca-2019-0017.
[PMID] 31385522.
2019
A case for genotype-guided pain management.
Pharmacogenomics.
20(10):705-708
[DOI] 10.2217/pgs-2019-0068.
[PMID] 31368851.
2019
Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(10):2264-2274
[DOI] 10.1038/s41436-019-0500-7.
[PMID] 30926959.
2019
Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome.
Cardiovascular drugs and therapy.
33(5):533-546
[DOI] 10.1007/s10557-019-06896-8.
[PMID] 31367811.
2019
CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(8):1842-1850
[DOI] 10.1038/s41436-018-0431-8.
[PMID] 30670877.
2019
Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
Genetic testing and molecular biomarkers.
23(3):209-214
[DOI] 10.1089/gtmb.2018.0298.
[PMID] 30758238.
2019
Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations.
Clinical pharmacokinetics.
58(8):1077-1089
[DOI] 10.1007/s40262-019-00745-5.
[PMID] 30815847.
2019
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.
Clinical pharmacology and therapeutics.
105(6):1477-1491
[DOI] 10.1002/cpt.1323.
[PMID] 30506689.
2019
Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing.
Genetics in medicine : official journal of the American College of Medical Genetics.
21(10):2255-2263
[DOI] 10.1038/s41436-019-0484-3.
[PMID] 30894703.
2019
Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.
The Journal of molecular diagnostics : JMD.
21(5):746-755
[DOI] 10.1016/j.jmoldx.2019.04.003.
[PMID] 31075510.
2018
Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.
JAMA.
320(16):1670-1677
[DOI] 10.1001/jama.2018.14955.
[PMID] 30357299.
2018
Clinical application of pharmacogenetics in pain management.
Personalized medicine.
15(2):117-126
[DOI] 10.2217/pme-2017-0032.
[PMID] 29714124.
2018
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Journal of translational medicine.
16(1)
[DOI] 10.1186/s12967-018-1469-8.
[PMID] 29642909.
2018
Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.
Contemporary clinical trials.
68:7-13
[DOI] 10.1016/j.cct.2018.03.001.
[PMID] 29535047.
2018
Endothelial nitric oxide synthase genotype is associated with pulmonary hypertension severity in left heart failure patients.
Pulmonary circulation.
8(2)
[DOI] 10.1177/2045894018773049.
[PMID] 29718770.
2018
Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
Pharmacotherapy.
38(2):205-216
[DOI] 10.1002/phar.2077.
[PMID] 29286540.
2018
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.
Public health genomics.
21(5-6):217-227
[DOI] 10.1159/000500725.
[PMID] 31189173.
2018
Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned.
Clinical and translational science.
11(2):175-181
[DOI] 10.1111/cts.12533.
[PMID] 29351371.
2018
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.
11(2):181-191
[DOI] 10.1016/j.jcin.2017.07.022.
[PMID] 29102571.
2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Clinical pharmacology and therapeutics.
104(4):664-674
[DOI] 10.1002/cpt.1006.
[PMID] 29280137.
2018
Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.
Clinical pharmacology and therapeutics.
104(5):957-965
[DOI] 10.1002/cpt.1012.
[PMID] 29315506.
2018
Pharmacogenetic and clinical predictors of response to clopidogrel plus aspirin after acute coronary syndrome in Egyptians.
Pharmacogenetics and genomics.
28(9):207-213
[DOI] 10.1097/FPC.0000000000000349.
[PMID] 30188374.
2018
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.
Clinical pharmacology and therapeutics.
103(5):778-786
[DOI] 10.1002/cpt.1048.
[PMID] 29460415.
2018
Role of genetic testing in patients undergoing percutaneous coronary intervention.
Expert review of clinical pharmacology.
11(2):151-164
[DOI] 10.1080/17512433.2017.1353909.
[PMID] 28689434.
2017
Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.
Clinical pharmacology and therapeutics.
101(5):675-683
[DOI] 10.1002/cpt.558.
[PMID] 28032893.
2017
Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype.
Pharmacogenomics.
18(18):1643-1648
[DOI] 10.2217/pgs-2017-0103.
[PMID] 29053440.
2017
Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network.
BMC medical genomics.
10(1)
[DOI] 10.1186/s12920-017-0273-2.
[PMID] 28532511.
2017
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Clinical pharmacology and therapeutics.
102(3):397-404
[DOI] 10.1002/cpt.668.
[PMID] 28198005.
2017
Correlations between the enantio- and regio-selective metabolisms of warfarin.
Pharmacogenomics.
18(2):133-142
[DOI] 10.2217/pgs-2016-0149.
[PMID] 27995809.
2017
Cross-Validation of High-Resolution Melting Analysis-Based Genotyping Platform.
Genetic testing and molecular biomarkers.
21(4):259-264
[DOI] 10.1089/gtmb.2016.0317.
[PMID] 28384046.
2017
Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.
Interventional cardiology clinics.
6(1):141-149
[DOI] 10.1016/j.iccl.2016.08.010.
[PMID] 27886818.
2017
Genotype-guided dosing of warfarin through modeling and simulation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
109S:S9-S14
[DOI] 10.1016/j.ejps.2017.05.017.
[PMID] 28502675.
2017
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Pharmacogenetics and genomics.
27(5):190-196
[DOI] 10.1097/FPC.0000000000000277.
[PMID] 28306618.
2017
Institutional profile: University of Florida Health Personalized Medicine Program.
Pharmacogenomics.
18(5):421-426
[DOI] 10.2217/pgs-2017-0028.
[PMID] 28346068.
2017
Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
Journal of thrombosis and haemostasis : JTH.
15(4):735-743
[DOI] 10.1111/jth.13639.
[PMID] 28135054.
2017
Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.
The British journal of dermatology.
177(4):1102-1112
[DOI] 10.1111/bjd.15498.
[PMID] 28346659.
2017
Matrix Metalloproteinase Polymorphisms in Patients with Floppy Mitral Valve/Mitral Valve Prolapse (FMV/MVP) and FMV/MVP Syndrome.
Cardiology.
138(3):179-185
[DOI] 10.1159/000477656.
[PMID] 28750369.
2017
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
Expert review of cardiovascular therapy.
15(8):581-589
[DOI] 10.1080/14779072.2017.1355236.
[PMID] 28699807.
2017
Population differences in S-warfarin pharmacokinetics among African Americans, Asians and whites: their influence on pharmacogenetic dosing algorithms.
The pharmacogenomics journal.
17(6):494-500
[DOI] 10.1038/tpj.2016.57.
[PMID] 27503578.
2017
Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now.
Pharmaceutical research.
34(8):1551-1555
[DOI] 10.1007/s11095-017-2163-x.
[PMID] 28466392.
2017
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.
Clinical and translational science.
10(3):143-146
[DOI] 10.1111/cts.12456.
[PMID] 28294551.
2017
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
Clinical pharmacology and therapeutics.
102(3):502-510
[DOI] 10.1002/cpt.630.
[PMID] 28090649.
2017
Time to revisit warfarin pharmacogenetics.
Future cardiology.
13(6):511-513
[DOI] 10.2217/fca-2017-0061.
[PMID] 28967279.
2017
Warfarin Pharmacogenomics in Diverse Populations.
Pharmacotherapy.
37(9):1150-1163
[DOI] 10.1002/phar.1982.
[PMID] 28672100.
2016
Cardiovascular Pharmacogenomics–Implications for Patients With CKD.
Advances in chronic kidney disease.
23(2):82-90
[DOI] 10.1053/j.ackd.2015.12.001.
[PMID] 26979147.
2016
Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure.
Journal of cardiac failure.
22(9):692-9
[DOI] 10.1016/j.cardfail.2015.12.016.
[PMID] 26721774.
2016
Clopidogrel pharmacogenetics: from evidence to implementation.
Future cardiology.
12(5):511-4
[DOI] 10.2217/fca-2016-0045.
[PMID] 27539287.
2016
Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course.
American journal of pharmaceutical education.
80(7)
[PMID] 27756930.
2016
Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.
Clinical and translational science.
9(1):36-42
[DOI] 10.1111/cts.12385.
[PMID] 26751406.
2016
Implementation of inpatient models of pharmacogenetics programs.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
73(23):1944-1954
[PMID] 27864202.
2016
Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges.
Clinical and translational science.
9(5):233-245
[DOI] 10.1111/cts.12404.
[PMID] 27214750.
2016
Novel genetic predictors of venous thromboembolism risk in African Americans.
Blood.
127(15):1923-9
[DOI] 10.1182/blood-2015-09-668525.
[PMID] 26888256.
2016
Population-specific single-nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans.
Molecular genetics & genomic medicine.
4(5):513-20
[DOI] 10.1002/mgg3.226.
[PMID] 27652279.
2016
The IGNITE network: a model for genomic medicine implementation and research.
BMC medical genomics.
9
[DOI] 10.1186/s12920-015-0162-5.
[PMID] 26729011.
2015
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms.
Pharmacogenomics.
16(3):217-25
[DOI] 10.2217/pgs.14.160.
[PMID] 25712185.
2015
Genes affecting warfarin response-interactive or additive?
Journal of clinical pharmacology.
55(3):258-60
[DOI] 10.1002/jcph.425.
[PMID] 25385663.
2015
Genome-wide association study of warfarin maintenance dose in a Brazilian sample.
Pharmacogenomics.
16(11):1253-63
[DOI] 10.2217/PGS.15.73.
[PMID] 26265036.
2015
Pharmacogenomics in cardiology–genetics and drug response: 10 years of progress.
Future cardiology.
11(3):281-6
[DOI] 10.2217/fca.15.20.
[PMID] 26021633.
2015
Pharmacogenomics of hypertension and heart disease.
Current hypertension reports.
17(9)
[DOI] 10.1007/s11906-015-0586-5.
[PMID] 26272307.
2015
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Pharmacogenetics and genomics.
25(2):73-81
[DOI] 10.1097/FPC.0000000000000108.
[PMID] 25461246.
2015
Warfarin pharmacogenetics.
Trends in cardiovascular medicine.
25(1):33-41
[DOI] 10.1016/j.tcm.2014.09.001.
[PMID] 25282448.
2014
Addition of Cyp2C9{*}5,{*}6,{*}8,{*}11 and Rs12777823 Genotypes Into An Existing Warfarin Dosing Algorithm Improves Algorithm Performance for African Americans.
Pharmacotherapy.
34(10):E220-E221
2014
Barriers To Implementing Pharmacogenetic Testing in An Urban Population.
Pharmacotherapy.
34(10)
2014
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.
The pharmacogenomics journal.
14(3):223-8
[DOI] 10.1038/tpj.2013.34.
[PMID] 24018621.
2014
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.
Blood.
124(14):2298-305
[DOI] 10.1182/blood-2014-04-568436.
[PMID] 25079360.
2014
Genotype-guided dosing of vitamin K antagonists.
The New England journal of medicine.
370(18)
[DOI] 10.1056/NEJMc1402521.
[PMID] 24785218.
2014
Pyrosequencing of the CYP2C9 -1766T>C polymorphism as a means of detecting the CYP2C9*8 allele.
Pharmacogenomics.
15(13):1717-22
[DOI] 10.2217/pgs.14.130.
[PMID] 25410896.
2014
Stakeholder views on pharmacogenomic testing.
Pharmacotherapy.
34(2):151-65
[DOI] 10.1002/phar.1364.
[PMID] 24167008.
2014
Warfarin dose requirements in a patient with the CYP2C9*14 allele.
Pharmacogenomics.
15(7):909-14
[DOI] 10.2217/pgs.14.47.
[PMID] 24956244.
2014
Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations.
Clinical pharmacology and therapeutics.
95(3):242-4
[DOI] 10.1038/clpt.2013.209.
[PMID] 24548987.
2014
Warfarin pharmacogenetics: to genotype or not to genotype, that is the question.
Clinical pharmacology and therapeutics.
96(1):22-4
[DOI] 10.1038/clpt.2014.78.
[PMID] 24942399.
2013
A pharmacogenetics service experience for pharmacy students, residents, and fellows.
American journal of pharmaceutical education.
77(8)
[DOI] 10.5688/ajpe778175.
[PMID] 24159216.
2013
Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure.
PloS one.
8(7)
[DOI] 10.1371/journal.pone.0071268.
[PMID] 23936266.
2013
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
Pharmacogenetics and genomics.
23(4):228-31
[DOI] 10.1097/FPC.0b013e32835e95c7.
[PMID] 23376925.
2013
Expression Quantitative Trait Loci Analysis of Stable Warfarin Dose Identifies Novel Associations: Finding Signal Within the Noise
Clinical Pharmacology & Therapeutics.
93
2013
Feasibility of implementing a comprehensive warfarin pharmacogenetics service.
Pharmacotherapy.
33(11):1156-64
[DOI] 10.1002/phar.1329.
[PMID] 23864527.
2013
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Lancet (London, England).
382(9894):790-6
[DOI] 10.1016/S0140-6736(13)60681-9.
[PMID] 23755828.
2013
Pathway analysis of genome-wide data improves warfarin dose prediction.
BMC genomics.
14 Suppl 3(Suppl 3)
[DOI] 10.1186/1471-2164-14-S3-S11.
[PMID] 23819817.
2013
Personalized medicine in cardiology: the time for genotype-guided therapy is now.
Future cardiology.
9(4):459-64
[DOI] 10.2217/fca.13.35.
[PMID] 23834684.
2013
Pharmacogenetics and cardiovascular disease–implications for personalized medicine.
Pharmacological reviews.
65(3):987-1009
[DOI] 10.1124/pr.112.007252.
[PMID] 23686351.
2013
Race influences the safety and efficacy of spironolactone in severe heart failure.
Circulation. Heart failure.
6(5):970-6
[DOI] 10.1161/CIRCHEARTFAILURE.113.000530.
[PMID] 23940307.
2013
VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians.
Thrombosis and haemostasis.
109(6):1045-50
[DOI] 10.1160/TH12-10-0789.
[PMID] 23571513.
2012
Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
Pharmacogenetics and genomics.
22(2):152-8
[DOI] 10.1097/FPC.0b013e32834f288f.
[PMID] 22158446.
2012
Cost is not a barrier to implementing clopidogrel pharmacogenetics.
Pharmacotherapy.
32(4):299-303
[DOI] 10.1002/j.1875-9114.2012.01107.x.
[PMID] 22461119.
2012
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
Clinical pharmacology and therapeutics.
91(4):660-5
[DOI] 10.1038/clpt.2011.269.
[PMID] 22378156.
2012
Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.
Pharmacogenomics.
13(16):1925-35
[DOI] 10.2217/pgs.12.164.
[PMID] 23215885.
2012
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
Clinical pharmacology and therapeutics.
92(6):746-56
[DOI] 10.1038/clpt.2012.184.
[PMID] 23132553.
2012
Tailoring drug therapy based on genotype.
Journal of pharmacy practice.
25(4):413-6
[DOI] 10.1177/0897190012448311.
[PMID] 22907842.
2012
The future of warfarin pharmacogenetics in under-represented minority groups.
Future cardiology.
8(4):563-76
[DOI] 10.2217/fca.12.31.
[PMID] 22871196.
2011
Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients.
Pharmacotherapy.
31(8):785-92
[DOI] 10.1592/phco.31.8.785.
[PMID] 21923605.
2011
Bleeding incidence with concomitant use of antidepressants and warfarin.
Therapeutic drug monitoring.
33(4):433-8
[DOI] 10.1097/FTD.0b013e318224996e.
[PMID] 21743381.
2011
Pharmacogenomics of warfarin dose requirements in Hispanics.
Blood cells, molecules & diseases.
46(2):147-50
[DOI] 10.1016/j.bcmd.2010.11.005.
[PMID] 21185752.
2011
Pharmacogenomics: application to the management of cardiovascular disease.
Clinical pharmacology and therapeutics.
90(4):519-31
[DOI] 10.1038/clpt.2011.179.
[PMID] 21918509.
2011
Role of cytochrome P450 genotype in the steps toward personalized drug therapy.
Pharmacogenomics and personalized medicine.
4:123-36
[DOI] 10.2147/PGPM.S15497.
[PMID] 23226058.
2011
Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.
Pharmacotherapy.
31(12):1192-207
[DOI] 10.1592/phco.31.12.1192.
[PMID] 22122181.
2011
The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
Clinical pharmacology and therapeutics.
89(3):408-15
[DOI] 10.1038/clpt.2010.322.
[PMID] 21270790.
2010
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
Clinical pharmacology and therapeutics.
87(4):445-51
[DOI] 10.1038/clpt.2009.291.
[PMID] 20200517.
2010
Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
Pharmacotherapy.
30(1):1-9
[DOI] 10.1592/phco.30.1.1.
[PMID] 20030467.
2010
Clopidogrel and proton pump inhibitors: between a rock and a hard place.
Pharmacotherapy.
30(8):762-5
[DOI] 10.1592/phco.30.8.762.
[PMID] 20653351.
2010
Genetic and clinical predictors of warfarin dose requirements in African Americans.
Clinical pharmacology and therapeutics.
87(4):459-64
[DOI] 10.1038/clpt.2009.223.
[PMID] 20072124.
2010
Warfarin dosing in patients with impaired kidney function.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
56(5):823-31
[DOI] 10.1053/j.ajkd.2010.05.023.
[PMID] 20709439.
2010
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Blood.
115(18):3827-34
[DOI] 10.1182/blood-2009-12-255992.
[PMID] 20203262.
2009
Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population.
The Annals of pharmacotherapy.
43(7):1165-72
[DOI] 10.1345/aph.1L707.
[PMID] 19549747.
2009
Genomics and the efficacy of aspirin in the treatment of cerebrovascular disease.
Current treatment options in cardiovascular medicine.
11(3):191-200
[PMID] 19433014.
2009
Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke.
Cerebrovascular diseases (Basel, Switzerland).
27(6):585-93
[DOI] 10.1159/000214223.
[PMID] 19390185.
2009
Predictors of unstable anticoagulation in African Americans.
Journal of thrombosis and thrombolysis.
27(4):430-7
[DOI] 10.1007/s11239-008-0236-8.
[PMID] 18563532.
2009
The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.
European journal of clinical pharmacology.
65(7):651-8
[DOI] 10.1007/s00228-009-0646-3.
[PMID] 19357842.
2009
Warfarin pharmacogenomics.
Current opinion in molecular therapeutics.
11(3):243-51
[PMID] 19479657.
2008
Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography.
The pharmacogenomics journal.
8(6):408-15
[DOI] 10.1038/sj.tpj.6500490.
[PMID] 18253135.
2008
Cytochrome P450 2C9 mediated metabolism in people with and without cancer.
International journal of clinical pharmacology and therapeutics.
46(7):365-74
[PMID] 18793590.
2008
Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression.
Journal of the renin-angiotensin-aldosterone system : JRAAS.
9(3):146-53
[DOI] 10.1177/1470320308096367.
[PMID] 18957385.
2008
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
Blood.
112(4):1013-21
[DOI] 10.1182/blood-2008-03-144899.
[PMID] 18523153.
2007
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Pharmacotherapy.
27(6):801-12
[PMID] 17542763.
2007
beta-adrenergic receptor pharmacogenetics.
Future cardiology.
3(3):229-32
[DOI] 10.2217/14796678.3.3.229.
[PMID] 19804212.
2007
Factors influencing warfarin dose requirements in African-Americans.
Pharmacogenomics.
8(11):1535-44
[PMID] 18034618.
2007
Markers of cardiac collagen turnover are similar in patients with mild and more severe symptoms of heart failure.
Congestive heart failure (Greenwich, Conn.).
13(5):275-9
[PMID] 17917494.
2006
Pharmacogenomics in heart failure: individualizing therapy based on genotype.
Future cardiology.
2(2):129-31
[DOI] 10.2217/14796678.2.2.129.
[PMID] 19804067.
2006
Racial differences in potassium response to spironolactone in heart failure.
Congestive heart failure (Greenwich, Conn.).
12(4):200-5
[PMID] 16894278.
2006
Sex difference in the antiplatelet effect of aspirin in patients with stroke.
The Annals of pharmacotherapy.
40(5):812-7
[PMID] 16608908.
2005
Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study.
International journal of obesity (2005).
29(7):746-54
[PMID] 15917856.
2005
Cardiovascular pharmacogenomics.
Experimental physiology.
90(3):283-9
[PMID] 15778411.
2004
Hyperkalemia after the publication of RALES.
The New England journal of medicine.
351(23):2448-50; author reply 2448
[PMID] 15580677.
2004
New treatment option for heart failure patients: eplerenone.
The Journal of cardiovascular nursing.
19(6):390-5
[PMID] 15529060.
2004
Racial differences in patients’ potassium concentrations during spironolactone therapy for heart failure.
Pharmacotherapy.
24(6):750-6
[PMID] 15222665.
2002
Pharmacogenetics of cardiovascular drugs.
Briefings in Functional Genomics & Proteomics.
1(1):66-79
[PMID] 15251067.
Grants
Jul 2024
ACTIVE
Development of Integrated Precision Medicine Models in Adults with Cardiovascular Disease
Role: Co-Investigator
Funding: NATL INST OF HLTH NHLBI
Jul 2024
ACTIVE
Adding preemptive pharmacogenetic testing to UF Health clinical genome sequence testing
Role: Co-Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Jul 2023
ACTIVE
Genetic Polymorphisms to Predict Response of Aneurysm Healing
Role: Co-Investigator
Funding: THE ANEURYSM AND AVM FOUNDATION
Jul 2023
ACTIVE
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Jul 2022
– Dec 2023
Integrated, Individualized, and Intelligent Prescribing (I3P) Clinical Trial Network
Role: Principal Investigator
Funding: VANDERBILT UNIVERSITY MEDICAL CENTER
via NATL INST OF HLTH NHGRI
Sep 2021
ACTIVE
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Role: Co-Investigator
Funding: NATL INST OF HLTH NINDS
Sep 2021
ACTIVE
Preemptive pharmacogenetic testing in medically underserved populations
Role: Co-Investigator
Funding: NATL INST OF HLTH NHGRI
Aug 2021
ACTIVE
Leveraging the Microbiome, Local Admixture, and Machine Learning to Optimize Anticoagulant Pharmacogenomics in Medically Underserved Patients
Role: Principal Investigator
Funding: UNIVERSITY OF ARIZONA
via NATL INST OF HLTH NHLBI
Aug 2020
– Jan 2022
Identifying Predictors of Spironolactone Response in Patients with Heart Failure with Preserved Ejection Fraction
Role: Other
Funding: NATL INST OF HLTH NHLBI
Jul 2020
ACTIVE
Precision antiplatelet therapy after percutaneous coronary intervention
Role: Principal Investigator
Funding: NATL INST OF HLTH NHLBI
Sep 2018
ACTIVE
Sparking Advancements in Genomic Medicine?
Role: Principal Investigator
Funding: NATL INST OF HLTH NHGRI
Apr 2018
– Sep 2019
Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery
Role: Principal Investigator
Funding: UF HEALTH SHANDS HOSPITAL
Apr 2018
– Jul 2019
Together: Transforming and Translating Discovery to Improve Health
Role: Project Manager
Funding: NATL INST OF HLTH NCATS
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Jun 2016
– Oct 2018
Development and analytic validation of a customized pharmacogenomics panel
Role: Principal Investigator
Funding: CANON BIOMEDICAL INC
Sep 2015
– Aug 2016
2015 Mallinckrodt Research Fellowship Award
Role: Principal Investigator
Funding: *MALLINCKRODT PHARMACEUTICALS-Bankrupt
Sep 2014
– Feb 2019
Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Cardiovascular Drugs
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Education
Doctor of Pharmacy
1997
·
University of Georgia
Contact Details
Phones:
- Business:
- (352) 273-8245
Emails:
- Business:
- lcavallari@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100486
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100486
GAINESVILLE FL 32610